Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
basiliximab + tacrolimus + mycophenolate mofetil + prednisone
- Development stage
- Unknown
- Lead developer
- Unidad de Investigación Médica en Enfermedades Renales
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This entry refers to a specific immunosuppressive regimen evaluated by the Unidad de Investigación Médica en Enfermedades Renales for the prevention of kidney transplant rejection. The protocol, known as Early Steroid Withdrawal (ESW), utilizes an induction phase with the monoclonal antibody basiliximab, followed by a maintenance triple therapy consisting of the calcineurin inhibitor tacrolimus, the antimetabolite mycophenolate mofetil, and a rapidly tapered course of corticosteroids (methylprednisolone/prednisone) that is completely withdrawn by the fifth day post-transplantation. The regimen is designed to minimize steroid-related morbidity, such as hypertension and dyslipidemia, in low-immunological-risk living-donor transplant recipients while maintaining adequate immunosuppression to prevent acute rejection.
- Brand names
- SimulectPrografCellCeptDeltasone
- Other names
- Early Steroid Withdrawal protocolESW regimen
02
Targets
CN (Calcineurin)GR (Glucocorticoid receptor)IMPDH (Inosine-5'-monophosphate dehydrogenase 1)IL2RA (Interleukin-2 receptor alpha subunit)FKBP1A
Beyond the preview
Go deeper on basiliximab + tacrolimus + mycophenolate mofetil + prednisone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on basiliximab + tacrolimus + mycophenolate mofetil + prednisone.